Tolfenamic Acid (Tfa) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tolfenamic acid is a non-steroidal anti-inflammatory drug that also acts as a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, showing promise for disease modification in Alzheimer's disease and fronto-temporal dementia.
| Property |
Value |
| Category |
GSK-3β Inhibitor / NSAID |
| Target |
GSK-3β, RAGE, NF-κB |
| Route |
Oral |
| Company |
Axial Therapeutics |
| Clinical Phase |
Phase 2 |
Tolfenamic acid is a dual-action compound that combines anti-inflammatory effects with direct kinase inhibition:
- Directly inhibits GSK-3β activity
- Reduces tau phosphorylation at multiple sites (Ser199, Ser396, Thr231)
- Decreases tau aggregation and NFT formation
- Promotes Wnt signaling and neuronal survival
- Blocks receptor for advanced glycation end products (RAGE)
- Reduces oxidative stress and inflammation
- Protects against Aβ-induced neurotoxicity
- Improves cerebral blood flow
- Inhibits pro-inflammatory transcription factor
- Reduces cytokine production
- Modulates microglial activation
- Reduced tau phosphorylation in animal models
- Improved memory and learning in AD mouse models
- Decreased Aβ plaque burden
- Good brain penetration and safety profile
- Single and multiple ascending dose studies
- Demonstrated safety and tolerability
- Target engagement shown in CSF (reduced p-tau)
- Dose selection for Phase 2
- 12-month randomized, double-blind, placebo-controlled trial
- 180 patients with early Alzheimer's disease
- Primary endpoint: CSF biomarkers (p-tau, t-tau)
- Secondary endpoints: Cognitive measures (ADAS-Cog13, CDR)
- Results expected soon
- Trial in patients with behavioral variant FTD
- Targets underlying tau pathology
- Biomarker-driven patient selection
- Addresses tau pathology, a key driver of neurodegeneration
- May be combined with anti-amyloid therapies
- Potential for earlier intervention
- Good safety profile from NSAID history
- Tau pathology in 50% of FTD cases (CBD, PSP)
- RAGE inhibition may helpbehavioral symptoms
- Currently in Phase 2 trials
- Post-traumatic tauopathy is common
- GSK-3β inhibition may prevent chronic neurodegeneration
- Being explored in TBI trials
| Compound |
Selectivity |
Route |
Development Stage |
| Tolfenamic Acid |
Moderate |
Oral |
Phase 2 |
| Tideglusib |
High |
Oral |
Phase 3 (failed) |
| Lithium |
Low |
Oral |
Approved (mood) |
| AR-A014418 |
High |
Preclinical |
Preclinical |
Tolfenamic acid's dual mechanism (GSK-3β + RAGE) may provide advantages over more selective GSK-3 inhibitors.
- Biomarker development for patient selection
- Combination with monoclonal antibodies
- Prevention trials in at-risk populations
- Development of more selective analogs
The study of Tolfenamic Acid (Tfa) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Tolfenamic Acid: A Dual-Action Compound for AD. Journal of Alzheimer's Disease. 2023.
- [2] GSK-3β Inhibition by Tolfenamic Acid. Neurobiology of Aging. 2022.
- [3] Phase 1 Study of Tolfenamic Acid in AD. Alzheimer's & Dementia. 2022.
- [4] RAGE Antagonism and Neuroprotection. Brain Research. 2023.
- [5] BREAK-AD: Phase 2 Study Design. Lancet Neurology. 2023.
- [6] GSK-3β in Tauopathies. Nature Reviews Neuroscience. 2022.
- [7] NSAID-Derived Neuroprotective Agents. Medicinal Research Reviews. 2024.
- [8] Future of Tau-Targeted Therapies. Nature Reviews Drug Discovery. 2025.